Skip to main content
OpenTrials
Completed

NCT Number: NCT05306379

Drug-Drug Interaction Study to Investigate Effects of Voclosporin on Pharmacokinetics of Simvastatin

A single-center, open-label, Phase 1, drug-drug interaction study to investigate the effect of voclosporin on the pharmacokinetics of simvastatin and simvastatin acid in healthy volunteers.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Labcorp Clinical Research Unit

Dallas, Texas, 75247, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Written informed consent
  • Healthy male or female subjects aged >=18 and <=55 years
  • Body mass index >=18.0 and <32 kg/m2

Exclusion criteria

  • Abnormal ECG and/or prolonged QT interval
  • Subjects using nicotine products within 3 months prior to screening
  • Subjects who have lost or donated >450 mL of whole blood or blood products within 30 days prior to the Screening Visit.
  • Use of any prescription medication within 14 days prior to the first dose of study medication, or any over-the-counter products (including natural health products, e.g., food supplements, vitamins, herbal supplements) within 7 days prior to the first dose of study medication, except for topical products without significant systemic absorption.
  • Use of any drugs or substances known to induce or inhibit hepatic drug metabolism within 28 days prior to administration of the study medication
  • Consumption of grapefruit or grapefruit juice, pomelo or star fruit within 7 days of first dose of study drug on Day 1
  • Use of hormonal contraception or hormone replacement therapy within 14 days prior to first dose of study drug.
  • No COVID-19 vaccines are allowed within 28 days prior to first dose of study drug.
  • History of or current alcohol abuse or drug addiction
  • Subjects who are pregnant or breast feeding
  • Subjects who have received any investigational drug within 30 days or 5 half-lives of the drug (whichever is longer) prior to screening.
  • Subjects who have any significant health issues as deemed by their treating physician/investigator

Treatment and study plan

simvastatin

Drug

Oral dose 40 mg

voclosporin

Drug

Oral dose 23.7 mg twice daily

Primary outcomes

  1. Pharmacokinetics of simvastatin and simvastatin acid (Cmax)

    Time frame: 9 days

    To evaluate the potential effect of multiple oral doses of voclosporin on the single-dose PK of simvastatin and the active metabolite simvastatin acid. Maximum observed concentration (Cmax).

  2. Pharmacokinetics of simvastatin and simvastatin acid (AUC)

    Time frame: 9 days

    To evaluate the potential effect of multiple oral doses of voclosporin on the single-dose PK of simvastatin and the active metabolite simvastatin acid. Area under the concentration-time curve (AUC) from time zero to infinity.

  3. Pharmacokinetics of simvastatin and simvastatin acid (AUC)

    Time frame: 9 days

    To evaluate the potential effect of multiple oral doses of voclosporin on the single-dose PK of simvastatin and the active metabolite simvastatin acid. Area under the concentration-time curve (AUC) time zero to last quantifiable concentration.

Secondary outcomes

  1. Pharmacokinetics of voclosporin (Cmax)

    Time frame: 9 days

    To evaluate voclosporin blood concentrations - Cmax.

  2. Pharmacokinetics of voclosporin (AUC)

    Time frame: 9 days

    To evaluate voclosporin blood concentrations - AUC from time zero to 12 hours.

  3. Pharmacokinetics of voclosporin (Tmax)

    Time frame: 9 days

    To evaluate voclosporin blood concentrations - Time to reach maximum observed plasma concentration (Tmax).

  4. Pharmacokinetics of voclosporin (Ctrough)

    Time frame: 9 days

    To evaluate voclosporin blood concentrations - Trough concentration (Ctrough) at the end of a dosing interval at steady state.

  5. Pharmacokinetics of voclosporin (CL/F)

    Time frame: 9 days

    To evaluate voclosporin blood concentrations - apparent clearance (CL/F).

  6. Number of participants with abnormal laboratory test results

    Time frame: Up to 2 weeks

    Number of subjects with abnormal laboratory test results (eg., hematology, biochemistry and urinalysis) will be assessed

  7. Number of participants with abnormal vital signs

    Time frame: Up to 2 weeks

    Number of participants with abnormal vital signs (eg., blood pressure, heart rate, body temperature, respiratory rate) will be assessed

  8. 12-Lead Electrocardiogram Assessment

    Time frame: Up to 2 weeks

    Standard 12-lead electrocardiograms (eg., QTcF interval) will be summarized by observed value and change from baseline values.

Sponsors and collaborators

Lead sponsor

Aurinia Pharmaceuticals Inc.

Industry

Registry information

Official study title

A Single Center, Open Label, Phase 1 Drug-Drug Interaction Study to Investigate the Effects of Voclosporin on the Pharmacokinetics of Simvastatin in Healthy Volunteers

Acronym: Statin-DDI

Important dates

Study start
2022
Primary completion
2022
Study completion
2022
First posted
Apr 1, 2022
Registry last updated
Apr 20, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.